Deal Watch: Teva Gets BioXcel Neuropsychiatric Assets In Bankruptcy Proceeding

Teva Pharmaceuticals acquired worldwide rights to BXCL501, a dexmedetomidine sublingual film under FDA review for at-home use in treating agitation linked to schizophrenia or bipolar disorders. The acquisition supports Teva's growth strategy and addresses an unmet patient need. BXCL501, if approved, would be the first FDA-approved at-home treatment for this condition. Teva aims to expand its neuroscience portfolio with this late-stage asset.

Teva Pharmaceuticals (TEVA) acquired worldwide rights to BXCL501, a dexmedetomidine sublingual film under FDA review for at-home use in treating agitation linked to schizophrenia or bipolar disorders. The deal, valued at up to $67.5M, expands Teva's neuroscience pipeline and aligns with its growth strategy. BXCL501, if approved, would be the first FDA-approved at-home treatment for this condition.

Teva Pharmaceuticals' Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia, was approved based on the SOLARIS trial. The trial showed significant symptom reduction compared to placebo. Dr. Christoph Correll, principal investigator, highlighted the benefits of long-acting injectables in reducing relapse and improving patient outcomes. Weltruza's subcutaneous administration aims to address patient reluctance and resource limitations of previous treatments.

Sanofi and Teva's IBD drug, duvakitug, showed long-term clinical remission in a Phase IIb trial. Analysts highlight its high potency and potential advantages over competitors. MSD and Roche have also invested heavily in anti-TL1A drugs, with MSD's tulisokibart and Roche's afimkibart in Phase III trials.

Teva (TEVA) and Sanofi (SNY) reported positive Phase 2b data for duvakitug, showing sustained benefits in ulcerative colitis and Crohn's disease through Week 44. Clinical remission rates varied by dose, with higher rates observed at 900 mg. The drug was generally well tolerated. Both companies are advancing duvakitug into Phase 3 studies. SNY is up 4.11% at $41.19, while TEVA is down 0.41% at $41.14.

Teva Pharmaceuticals and Sanofi reported positive long-term data for duvakitug, showing efficacy in ulcerative colitis and Crohn's disease over 44 weeks. The drug is under investigation, with no regulatory approval yet. Teva shares rose 0.87% to $41.64 in pre-market trading.